NCT03007810已完成1 期
An Ascending Single Dose Study of the Pharmacokinetics, Safety and Tolerability of Hemay005 in Healthy Male Subjects
Tianjin Hemay Bio-Tech Co., Ltd1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2016年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Number of adverse events and serious adverse events
研究概览
简要总结
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. This study is the first administration of Hemay005 in humans to establish the initial safety, tolerability, and pharmacokinetic profile following single doses of Hemay005. A total of approximately 44 subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg), approximately 8 healthy subjects will be enrolled (6 active and 2 placebo) at each dose cohort by sentinel method(1 active and 1 placebo,5 active and 1 placebo), with the exception of 10mg (4 active) cohort. This study includes an 28-day Screening Period, a 1-day Treatment Period, and an End of Study Visit occurring approximately 11days (±3 days) after study drug administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male subjects aged 18 to 60 years;
- •Bodyweight（BW）≥ 50kg, Body mass index (BMI) in 18-28 (including upper and lower limit of the range);
- •All male subjects must agree and commit to the use of a reliable contraceptive regimen(including vasoligation, abstinence, using a condom) for the duration of the study(from screening until 6 months after the last dose);
- •Ability to understand and be willing to sign a written informed consent before study entry;
- •Subjects would have good communication with the investigator and could comply with protocol.
排除标准
- •A history of clinically severe gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or haematological disorders;
- •Have a known history of hypersensitivity to any medicine or food, or allergy to the test article or any of the excipient of the test article;
- •Have a gastrointestinal, hepatic or renal condition that may influence drug absorption or metabolism;
- •A history of chronic infection (ie, tuberculosis);
- •A medical history of any clinically significant medical disease or surgery within 4 weeks of the screening;
- •Clinically significant laboratory abnormal results at screening or prior to the first dose of study drug;
- •Clinically significant abnormal 12-lead ECG or vital signs ( systolic pressure <90 mmHg or >140 mmHg, diastolic pressure <50 mmHg or >90 mmHg; radial pulse rate <50 bpm or >100 bpm);
- •Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening;
- •Recent history of frequent alcohol consumption, defined by average intake of greater than 14 units of alcohol per week (1 unit = 360 mL beer or 45 mL of spirits with 40% alcohol content, or 150 mL wine), Participants who are unable to abstain from smoking during the study or quitting smoking for less than 3 months;
- •Positive urine screen for drug and cigarettes, positive breath test for alcohol;
- •Subjects who use soft drugs (ie marijuana )within 3 months of the screening and entire study duration or hard drugs (ie cocaine, phencyclidine ) within 1 year of the screening and entire study duration;
- •Dietary habits or food intolerances which will interfere with the requirements for participants to consume a standardised diet whilst confined to the clinical unit;
- •Participants who eat special food (Including grapefruit and/or Xanthine diet) for 14 days prior to dosing or any caffeine containing food or drinks, i.e. chocolate for 48 hours prior to dosing or drinking alcohol for 24 hours prior to dosing and not will stop to intake above food and drinks;
- •Use of any drug that inhibits or induces hepatic metabolism of drugs within 30 days of planned study drug administration and entire study duration (e.g. inducers: barbiturates, carbamazepine, rifampicin, phenytoin, glucocorticoid and omeprazole; inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones and antihistamines);
- •Participant who received any medicine within 14 days of the initial dose of study drug;
- •Have received other clinical trials treatment within 3 months prior to study;
- •Participants who have donated of blood (>400 mL) within 4 weeks of the study, or plan to donate of blood during of the study and 4 weeks after the study;
- •Subjects cannot complete the study due to other reasons or by the investigator's judgment
研究组 & 干预措施
Hemay005
Experimental
Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
干预措施: Hemay005 (Drug)
Placebo
Placebo Comparator
Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
干预措施: Placebos (Drug)
结局指标
主要结局
Number of adverse events and serious adverse events
时间窗: Day 1 up to Day 11±3
次要结局
- Cmax(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- Tmax(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- AUC∞(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- t1/2(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- CL/F(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- AUCt(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- Vz/F(pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose)
- Cumulative urinary excretion(pre-dose, 0-4 hours，4-8 hours，8-12 hours，12-24 hours，24-36 hours，36-48 hours post-dose)
- Accumulative urine excretion rate(pre-dose, 0-4 hours，4-8 hours，8-12 hours，12-24 hours，24-36 hours，36-48 hours post-dose)
- Renal clearance(pre-dose, 0-4 hours，4-8 hours，8-12 hours，12-24 hours，24-36 hours，36-48 hours post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy SubjectsPsoriasisNCT04837235Tianjin Hemay Pharmaceutical Co., Ltd12
已完成
2 期
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisPsoriasisNCT04102241Tianjin Hemay Pharmaceutical Co., Ltd216
已完成
3 期
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque PsoriasisPsoriasisNCT04839328Tianjin Hemay Pharmaceutical Co., Ltd306
Unknown
1 期
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy SubjectsPsoriasisNCT03570346Tianjin Hemay Bio-Tech Co., Ltd24
撤回
不适用
Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older AdultsSarcopeniaNCT05458232University of Arkansas